PCSK9 and prostate carcinoma: Analysis on disease subtypes provided similar magnitude of association with genetically proxied PCSK9, although confidence intervals overlapped the null (early-onset prostate cancer: OR = 0.91, 95% CI = 0.91 to 1.03, P = 0.139; advanced prostate cancer: OR = 0.93, 95% CI = 0.86 to 1.01, P = 0.102).